Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple injection ease menopause pain? new study investigates

NCT ID NCT02739880

Symptom relief Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small pilot study tested whether injecting a gel-like substance (hyaluronic acid) into the vaginal area could help menopausal women with pain during sex and vaginal dryness. Twenty women received the injections and were followed for 8 weeks. The main goal was to see if the vaginal lining thickened, and researchers also checked for changes in acidity, bacteria, and overall comfort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

20 people

The number who actually took part.

Started

Jun 2017

Finished

Sep 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 69 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient must have given her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * The patient is available for 8 weeks of follow-up * The patient is menopausal (amenorrhea) for over 2 years and less than 10 years * The patient has a body mass index \<35 * The patient has sexual disorders (dyspareunia) or vaginal discomfort associated with vaginal dryness. Exclusion Criteria: * The patient is participating in another study * The patient is in an exclusion period determined by a previous study * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * The patient is pregnant or breastfeeding * The patient is not menopausal (both clinically and biologically) * The patient has a body mass index \> 35 * The patient has a genital prolapse higher than stage 2 with a surgical indication * The patient has stress incontinence with a surgical indication * The patient suffers from vaginismus * Presence of an untreated viral, fungal or bacterial vulvovaginal or urinary infection * Hemorrhagic or neoplastic genital pathologies * Existence of a hormone-dependent tumor, genital bleeding of unknown origin * Current treatments based on antihypertensives, steroid anti-inflammatory drugs, anticoagulants, major antidepressants, aspirin * Known hypersensitivity to hyaluronic acid or mannitol * Known hypersensitivity to Betadine * Known hypersensitivity to Lidocaine * Hypersensitivity to EMLA® * Previous urogynaecological vulvovaginal surgery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyspareunia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psychologic dyspareunia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyspareunia Menopause

Contacts and locations

Locations

  • CHRU de Nîmes - Hôpital Universitaire Carémeau

    Nîmes, 30029, France

  • Centre Médical KARIS

    Perpignan, 66000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.